keyword
MENU ▼
Read by QxMD icon Read
search

Denosumab

keyword
https://www.readbyqxmd.com/read/28432640/osteoporosis-bone-mineral-density-and-ckd-mbd-treatment-considerations
#1
REVIEW
Jordi Bover, Lucía Bailone, Víctor López-Báez, Silvia Benito, Paola Ciceri, Andrea Galassi, Mario Cozzolino
Osteoporosis and chronic kidney disease (CKD) have both independently important potential impact on bone health. A significant number of patients with CKD stages 3a-5D have been shown to have low bone mineral density (BMD), leading to a strikingly elevated risk of fractures (mainly hip fractures) and higher associated morbidity and mortality. Mechanical properties of bone beyond age and menopausal status are additionally affected by intrinsic uremic factors. Therefore, we review in this article not only general concepts of osteoporosis and related consequences, but also the diagnostic and therapeutic implications of low BMD and bone fractures in CKD, beyond increased vascular calcification...
April 21, 2017: Journal of Nephrology
https://www.readbyqxmd.com/read/28429555/management-of-mineral-and-bone-disorders-in-renal-transplant-recipients
#2
Matthew J Damasiewicz, Peter R Ebeling
The management of post-transplantation bone disease is a complex problem that remains under-appreciated in clinical practice. In these patients, pre-existing metabolic bone disorder is further impacted by the use of immunosuppressive medications (glucocorticoids and calcineurin-inhibitors), variable post-transplantation renal allograft function and post-transplantation diabetes mellitus. The treatment of post-transplantation bone loss should begin pre-transplantation. All patients active on transplant waiting lists should be screened for bone disease...
March 2017: Nephrology
https://www.readbyqxmd.com/read/28429148/an-observational-time-and-motion-study-of-denosumab-subcutaneous-injection-and-zoledronic-acid-intravenous-infusion-in-patients-with-metastatic-bone-disease-results-from-three-european-countries
#3
Jean-Jacques Body, Francesca Gatta, Erwin De Cock, Sunning Tao, Persefoni Kritikou, Pauline Wimberger, Jeroen Mebis, Marc Peeters, Paolo Pedrazzoli, Augusto Caraceni, Vincenzo Adamo, Guy Hechmati
PURPOSE: Denosumab (administered via subcutaneous injection) demonstrated superior efficacy versus the intravenously administered zoledronic acid in the prevention of skeletal-related events in an integrated analysis of three head-to-head phase III trials in patients with bone metastases secondary to solid tumors. To date, no studies have evaluated treatment administration duration endpoints of these two agents. METHODS: A multinational, multi-site, observational time and motion study conducted in 10 day oncology units (DOUs) across Belgium, Germany, and Italy...
April 21, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28425086/the-clinical-benefits-of-denosumab-for-prophylaxis-of-steroid-induced-osteoporosis-in-patients-with-pulmonary-disease
#4
Shigeo Ishiguro, Kentaro Ito, Shigenori Nakagawa, Osamu Hataji, Akihiro Sudo
Previous reports demonstrated that bone density decreased rapidly during the initial few months of steroid therapy and continued decreasing at a rate of 2 to 4% annually. Our data indicates that denosumab can also play a role in the treatment of osteoporosis in the steroid-taking population. INTRODUCTION: Respiratory physicians are often faced with the dilemma that long-term steroid use will deteriorate bone mineral density and quality. Previous reports demonstrated that bone density decreased 8 to 12% during the initial few months of steroid therapy then continued decreasing at a rate of 2 to 4% annually...
December 2017: Archives of Osteoporosis
https://www.readbyqxmd.com/read/28416991/can-denosumab-be-a-substitute-competitor-or-complement-to-bisphosphonates
#5
REVIEW
Su Young Kim, Hwoe Gyeong Ok, Christof Birkenmaier, Kyung Hoon Kim
Osteoblasts, originating from mesenchymal cells, make the receptor activator of the nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) in order to control differentiation of activated osteoclasts, originating from hematopoietic stem cells. When the RANKL binds to the RANK of the pre-osteoclasts or mature osteoclasts, bone resorption increases. On the contrary, when OPG binds to the RANK, bone resorption decreases. Denosumab (AMG 162), like OPG (a decoy receptor), binds to the RANKL, and reduces binding between the RANK and the RANKL resulting in inhibition of osteoclastogenesis and reduction of bone resorption...
April 2017: Korean Journal of Pain
https://www.readbyqxmd.com/read/28413771/management-of-aromatase-inhibitor-associated-bone-loss-aibl-in-postmenopausal-women-with-hormone-sensitive-breast-cancer-joint-position-statement-of-the-iof-cabs-ects-ieg-esceo-ims-and-siog
#6
REVIEW
Peyman Hadji, Matti S Aapro, Jean-Jacques Body, Michael Gnant, Maria Luisa Brandi, Jean Yves Reginster, M Carola Zillikens, Claus-C Glüer, Tobie de Villiers, Rod Baber, G David Roodman, Cyrus Cooper, Bente Langdahl, Santiago Palacios, John Kanis, Nasser Al-Daghri, Xavier Nogues, Erik Fink Eriksen, Andreas Kurth, Rene Rizzoli, Robert E Coleman
BACKGROUND: Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fractures, particularly during aromatase inhibitor (AI) therapy. Recently, a number of studies on additional fracture related risk factors, new treatment options as well as real world studies demonstrating a much higher fracture rate than suggested by randomized clinical controlled trials (RCTs). Therefore, this updated algorithm was developed to better assess fracture risk and direct treatment as a position statement of several interdisciplinary cancer and bone societies involved in the management of AI-associated bone loss (AIBL)...
June 2017: Journal of Bone Oncology
https://www.readbyqxmd.com/read/28413541/clival-giant-cell-tumor-a-rare-case-report-and-review-of-literature-with-respect-to-current-line-of-management
#7
Mohana Rao Patibandla, Amit Kumar Thotakura, Marabathina Nageswara Rao, Gokul Chowdary Addagada, Manisha Chowdary Nukavarapu, Manas Kumar Panigrahi, Shantiveer Uppin, Sundaram Challa, Srinivas Dandamudi
Giant-cell tumor (GCT) involving the skull base is rare. Sphenoid bone is the most commonly involved bone followed by petrous temporal bone. Histopathology and radiological features of these lesions are similar to GCT involving bone elsewhere. Unlike other sites, skull base is not an ideal site for the radical surgery. Hence adjuvant treatment has pivotal role. Radiation therapy with intensity-modulated radiation therapy, stereotactic radiosurgery or chemotherapy with adriamycin are promising as described in some case reports...
January 2017: Asian Journal of Neurosurgery
https://www.readbyqxmd.com/read/28411109/letter-to-the-editor-concerning-hajdu-cheney-syndrome-report-of-a-novel-notch2-mutation-and-treatment-with-denosumab-by-g-adami-et-al-bone-2016-92-150-156
#8
https://www.readbyqxmd.com/read/28401495/cessation-rate-of-anti-osteoporosis-treatments-and-risk-factors-in-spanish-primary-care-settings-a-population-based-cohort-analysis
#9
Elisa Martín-Merino, Consuelo Huerta-Álvarez, Daniel Prieto-Alhambra, Dolores Montero-Corominas
Among 95,057 patients ≥50 years with new anti-osteoporosis medications (AOM) (2001-2013) in primary care, 1-year cessation was 51% (28%-68%), higher in men, smokers, patients with missing lifestyle data, and out normal BMI, and lower in those aged 60-79, with recent fractures or other anti-osteoporotics, suggesting non-severe osteoporosis and less risk awareness. PURPOSE: Low compliance to anti-osteoporosis medications (AOM) has been previously reported. We aimed to estimate 1-year cessation rates of different AOMs as used in Spanish healthcare settings, and to identify associated risk factors...
December 2017: Archives of Osteoporosis
https://www.readbyqxmd.com/read/28397581/comparison-of-the-effects-of-denosumab-with-either-active-vitamin-d-or-native-vitamin-d-on-bone-mineral-density-and-bone-turnover-markers-in-postmenopausal-osteoporosis
#10
Takako Suzuki, Yukio Nakamura, Mizue Tanaka, Mikio Kamimura, Shota Ikegami, Shigeharu Uchiyama, Hiroyuki Kato
Osteoporosis is a worldwide health concern. Although treatment with denosumab plus the active vitamin D alfacalcidol has been found to improve femoral neck (FN) and distal forearm bone mineral density (BMD), there have been no reports on the efficacy or adverse effects of denosumab plus eldecalcitol (ELD) in primary osteoporosis patients. Fifty-six treatment-naïve post-menopausal women with primary osteoporosis were recruited and divided into denosumab plus native vitamin D or denosumab plus ELD. Ultimately, 26 subjects in the native vitamin D group and 24 in the ELD group were analyzed...
April 11, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28396950/giant-cell-tumor-of-the-thoracic-spine-completely-removed-by-total-spondylectomy-after-neoadjuvant-denosumab-therapy
#11
Noritaka Yonezawa, Hideki Murakami, Satoshi Kato, Akihiko Takeuchi, Hiroyuki Tsuchiya
PURPOSE: Denosumab, a novel monoclonal antibody that targets the receptor activator of nuclear factor-κB (RANK) ligand (RANKL), has recently been used to treat patients with giant cell tumor of bone (GCTB). However, few reports have described the clinical results of denosumab therapy for spinal GCTB and evaluated treatment efficacy with respect to the entirety of the resected vertebra after denosumab therapy. METHODS: We present the case of a 51-year-old man with T12 GCTB that was completely removed by a total spondylectomy following 10 courses of neoadjuvant denosumab therapy...
April 10, 2017: European Spine Journal
https://www.readbyqxmd.com/read/28396758/use-of-denosumab-in-recurrent-chondroblastoma-of-the-squamous-temporal-bone-a-case-report
#12
Nicholas Calvert, David Wood
Chondroblastoma is a rare, benign bone tumor that represents 1-2% of all primary bone tumors. Denosumab, a monoclonal antibody, has been demonstrated to inhibit the growth of giant cell tumors. We report a case of recurrent chondroblastoma of the squamous temporal bone that is currently suppressed with denosumab.
April 2017: Clinical Case Reports
https://www.readbyqxmd.com/read/28395318/benefits-and-harms-of-osteoporosis-medications-in-patients-with-chronic-kidney-disease-a-systematic-review-and-meta-analysis
#13
Lisa M Wilson, Casey M Rebholz, Ermias Jirru, Marisa Chi Liu, Allen Zhang, Jessica Gayleard, Yue Chu, Karen A Robinson
Background: Complications of chronic kidney disease (CKD) include weak bones and increased fracture risk. Purpose: To review the benefits and harms of osteoporosis medications (bisphosphonates, teriparatide, raloxifene, and denosumab) compared with placebo, usual care, or active control in terms of bone mineral density (BMD), fractures, and safety in patients with CKD. Data Sources: PubMed and the Cochrane Central Register of Controlled Trials from December 2006 through December 2016...
April 11, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28393590/feasibility-of-extended-dosing-intervals-of-denosumab
#14
Jacob K Kettle, Puja B Patel
Purpose Denosumab is a crucial supportive care agent for patients with advanced cancers affecting the bone. Despite the importance of treatment, logistical and financial obstacles hinder the ability to maintain long-term adherence. This analysis was designed to provide preliminary data regarding the feasibility of extended denosumab dosing intervals. Methods This retrospective, case cohort study was conducted on patients receiving treatment with denosumab for malignancies with bone involvement. A total of 60 patients were identified for analysis and were divided into cohorts according to the average number of days between denosumab doses...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28392837/denosumab-treatment-in-the-management-of-patients-with-advanced-prostate-cancer-clinical-evidence-and-experience
#15
REVIEW
Miriam Hegemann, Jens Bedke, Arnulf Stenzl, Tilman Todenhöfer
Osteoprotective therapies have become an essential component in the management of advanced prostate cancer (PC) patients as bone metastases (BMs) have a major impact on morbidity and mortality. Denosumab is a fully humanized antibody targeting the receptor activator of nuclear factor κB ligand (RANKL), which has been approved by the European Medicines Agency (EMA) in Europe and the United States (US) Food and Drug Administration (FDA) in the US for prevention of skeletal-related events (SREs) in patients with solid tumors and BMs, including PC...
March 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28389970/osteoporosis-a-discussion-on-the-past-5%C3%A2-years
#16
REVIEW
Kyle M Schweser, Brett D Crist
PURPOSE OF THE REVIEW: The purposes of this study are to examine the literature within the past 5 years regarding osteoporosis and offer a discussion on new topics and controversies. RECENT FINDINGS: Patient compliance with therapy remains an issue. The effectiveness of Vitamin D and calcium are being called into question Atypical femur fractures have been associated with bisphosphonate and denosumab use. Treatment is both surgical and pharmaceutical. A multidisciplinary approach to osteoporotic fractures is important and having some form of fracture liaison service (FLS) improves the efficacy of osteoporotic care and decreases secondary fractures...
April 7, 2017: Current Reviews in Musculoskeletal Medicine
https://www.readbyqxmd.com/read/28388533/brca1-haploinsufficiency-cell-autonomously-activates-rankl-expression-and-generates-denosumab-responsive-breast-cancer-initiating-cells
#17
Elisabet Cuyàs, Bruna Corominas-Faja, María Muñoz-San Martín, Begoña Martin-Castillo, Ruth Lupu, Joan Brunet, Joaquim Bosch-Barrera, Javier A Menendez
Denosumab, a monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), might be a novel preventative therapy for BRCA1-mutation carriers at high risk of developing breast cancer. Beyond its well-recognized bone-targeted activity impeding osteoclastogenesis, denosumab has been proposed to interfere with the cross-talk between RANKL-producing sensor cells and cancer-initiating RANK+ responder cells that reside within premalignant tissues of BRCA1-mutation carriers. We herein tested the alternative but not mutually exclusive hypothesis that BRCA1 deficiency might cell-autonomously activate RANKL expression to generate cellular states with cancer stem cell (CSC)-like properties...
March 25, 2017: Oncotarget
https://www.readbyqxmd.com/read/28387573/metformin-inhibits-rankl-and-sensitizes-cancer-stem-cells-to-denosumab
#18
Elisabet Cuyàs, Begoña Martin-Castillo, Joaquim Bosch-Barrera, Javier A Menendez
The increased propensity of BRCA1 mutation carriers to develop aggressive breast tumors with stem-like properties begins to be understood in terms of osteoprotegerin (OPG)-unrestricted cross-talk between RANKL-overproducing progesterone-sensor cells and cancer-initiating RANK(+) responder cells that reside within pre-malignant BRCA1(mut/+) breast epithelial tissue. We recently proposed that, in the absence of hormone influence, cancer-initiating cells might remain responsive to RANKL stimulation, and hence to the therapeutic effects of the anti-RANKL antibody denosumab because genomic instability induced by BRCA1 haploinsufficiency might suffice to cell-autonomously hyperactivate RANKL gene expression...
April 7, 2017: Cell Cycle
https://www.readbyqxmd.com/read/28382583/use-and-safety-of-denosumab-in-cancer-patients
#19
Alba Manzaneque, Cristian Chaguaceda, Mireia Mensa, Carla Bastida, Natàlia Creus-Baró
Background Few data have been reported on the use and safety of denosumab in patients with solid tumors and bone metastasis in clinical practice. Objectives To describe the use of denosumab and to analyze its adverse effects (AE) in tertiary hospital cancer outpatients. Methods Retrospective study of patients who started denosumab between January 2013 and June 2015. We recorded demographic, clinical, and treatment-related variables, as well as the reasons for discontinuation and AE. Results The study population comprised 104 patients, of whom 86 (82...
April 5, 2017: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/28381439/tumor-stroma-interactions-in-bone-metastasis-molecular-mechanisms-and-therapeutic-implications
#20
Hanqiu Zheng, Wenyang Li, Yibin Kang
Metastasis and associated complications are the major cause of death for cancer patients. The incidence of bone metastasis is among the highest in cancers arising from breast, prostate, and lung. Common skeletal-related events caused by bone metastasis include aberrant bone remodeling (osteolytic, osteoblastic, and mixed), bone pain, fracture, spinal cord compression, and life-threatening hypercalcemia. It is now known that interactions between tumor cells and bone stroma lie at the core of major steps of bone-metastasis progression...
April 5, 2017: Cold Spring Harbor Symposia on Quantitative Biology
keyword
keyword
8329
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"